News & Views
Telix Pharmaceuticals is pleased to announce we are participating at AusBiotech + Invest 2020 online conference to be held live 28th – 30th October 2020 and on-demand. Telix is pleased…
Read more
Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging of…
Read more
Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for the preparation of…
Read more
Telix announces first two patients dosed in phase I trial of lung & ovarian cancer…
Read more
Telix announces it has entered into a strategic collaboration agreement with Varian Medical…
Read more
Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging…
Read more
Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of multiple…
Read more
Telix announces the first patient has been dosed in a Phase I/II study of Telix’s renal cancer diagnostic imaging product TLX250-CDx in…
Read more
Telix will hold an investor conference call to present the Company’s H1 2020 financial results together with an update on Telix’s…
Read more
Telix announces it has submitted a Drug Master File to the FDA for TLX101 (4-[131I]Iodol-phenylalanine…
Read more